Biotech & Genomic Medicine

Baili Tianheng announced that the company recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial of its self-developed, world-first bispecific antibody drug conjugate Yizekang, also known as luncoitab, in combination with radiotherapy for locally advanced unresectable head and neck squamous cell carcinoma and other solid tumors has been approved. To date, the drug has initiated more than 45 clinical trials in China and the United States, including 20 Phase III clinical studies, and 9 indications have been included in the breakthrough therapy designation list by the Center for Drug Evaluation.

The US Food and Drug Administration granted Breakthrough Device designation to Natera's multi cancer early detection blood test, a move that reshapes how investors frame the company's diagnostics pipeline. The designation follows a strong run in Natera's share price, with a 30-day return of 21.31%, a 90-day move of 48.44%, a year-to-date gain of 75.10%, and a 1-year total shareholder return of 136.73%. The stock's latest close of $400.71 sits above the most followed fair value estimate of $355.93, which implies the shares are 13% overvalued under a 7.5% discount rate. By contrast, the Simply Wall St discounted cash flow model estimates a future cash flow value of $599.47, suggesting the shares trade about 33% below that level. Natera's investment in new product launches such as Fetal Focus NIPT, Signatera Genome, and AI-based biomarkers, along with its R&D pipeline, positions it to capture growth from long-term trends in personalized medicine and early detection, though tighter reimbursement rules or sustained high R&D spending could pressure profitability.

AbbVie received two FDA Breakthrough Therapy Designations for its experimental cancer drug telisotuzumab adizutecan in colorectal cancer and non small cell lung cancer. The designations apply to biomarker defined patient groups in those two large solid tumor indications, and they mark the first Breakthrough Therapy status for telisotuzumab adizutecan, which sits in AbbVie's antibody drug conjugate pipeline. Colorectal cancer and non small cell lung cancer together affect more than four million people worldwide each year, and the focus on biomarker defined groups, including c Met protein expressing NSCLC, points to narrower patient pools but potentially higher value treatment settings. The designations support the view that AbbVie needs its pipeline to replace aging blockbusters such as Humira and Imbruvica, with telisotuzumab adizutecan complementing oncology assets like etentamig. The next signpost is how the ongoing Phase 3 and Phase 2/3 telisotuzumab adizutecan studies progress and when AbbVie moves toward regulatory filings in colorectal cancer and non small cell lung cancer, building on the first in human M21 404 data.

3SBio subsidiaries Zhejiang Sunshine Mandi and Zhejiang Wansheng have signed an agreement with MindRank AI to commercialize MDR-001, an oral GLP-1 candidate in Phase 3 obesity trials. The deal lands as 3SBio shares trade at HK$15.07, with a 1-year total shareholder return down 45.58 percent, a 30-day share price return down 6.69 percent and a year-to-date share price return down 38.69 percent, even as the 3-year total shareholder return is up more than 2x. On valuation, 3SBio trades at a P/E of 3.9x against a Hong Kong Biotechs industry average of 17.3x and a peer group average of 36.2x, with an estimated fair P/E of 8.2x. A discounted cash flow model puts 3SBio's estimated future cash flow value at HK$33.62 versus the current HK$15.07 share price. Recent declines in revenue and net income, combined with the weak 1-year return, could pressure sentiment if MDR-001 progress disappoints.

Akeso, Inc. announced that the first patient has been dosed in a Phase III clinical study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in the neoadjuvant/adjuvant perioperative treatment of resectable microsatellite instability-high or mismatch repair-deficient colon cancer. The trial, designated COMPASSION-40/AK104-313, marks a significant new indication for cadonilimab beyond gastric, lung, and cervical cancers, and is the 13th Phase III or registrational study of the therapy conducted globally. Colorectal cancer is among the malignancies with the highest incidence and mortality worldwide, and patients with MSI-H/dMMR colon cancer derive limited benefit from conventional perioperative chemotherapy, with pathological response rates of only approximately 7%. No immunotherapy has yet been approved anywhere for the perioperative treatment of localized MSI-H/dMMR colon cancer. Supporting evidence comes from a prior Phase II study of cadonilimab monotherapy as neoadjuvant treatment in MSI-H/dMMR colorectal cancer, where data presented at the 2024 ESMO Immuno-Oncology Congress showed a pathological complete response rate of 84.6% and a major pathological response rate of 100% among patients who proceeded to surgery, with a manageable safety profile.

On October 10, the AI-Empowered Precision Diagnosis and Treatment of Lung Cancer Summit Forum and the launch ceremony for the National Respiratory Medicine Center's Lung Cancer Precision Diagnosis and Treatment Standardization Project, hosted by the National Respiratory Medicine Center of the First Affiliated Hospital of Guangzhou Medical University and the Guangdong Provincial Chest Disease Society, and organized by KingMed Diagnostics, was held in Guangzhou. At the event, DeepGEM 2.0, a multimodal AI model for lung cancer pathology genomics jointly developed by the First Affiliated Hospital of Guangzhou Medical University and KingMed Diagnostics, was officially released. A multicenter research project involving 50 medical institutions nationwide was also launched, marking the model's formal entry into large-scale clinical validation. According to Dr. Liu Si, head of KingMed Diagnostics' artificial intelligence division, DeepGEM 2.0 analyzes routine digital pathology slide images without requiring additional sampling and can deliver results in as little as one minute. Building on the original six genes—EGFR, KRAS, ALK, ROS1, TP53, and LRP1B—it adds BRAF, ERBB2, FGFR, MET, NTRK, and RET, bringing the total to 12 genes and achieving full coverage of genes corresponding to approved targeted therapies for lung cancer in China. The model will subsequently be deployed in a lightweight form at more than 500 medical institutions. Using an approach of AI-based initial screening combined with targeted validation of specific genes, it is expected to reduce the cost of lung cancer genetic testing to the range of several hundred yuan. Zhong Nanshan, an academician of the Chinese Academy of Engineering and director of the Guangzhou National Laboratory, said that in the new AI era, scientific research must aim high while serving the people. In 2025, the First Affiliated Hospital of Guangzhou Medical University, together with KingMed Diagnostics and Tencent, released DeepGEM, a multimodal pathology genomics model capable of identifying genes from images. After nearly a year of multicenter data validation and clinical refinement, and iterative optimization using nearly 8,000 digital pathology slides from 31 provinces across China provided by KingMed Diagnostics, it has been upgraded to version 2.0. Liang Yaoming, chairman and CEO of KingMed Diagnostics, said that AI pathology technology brings new opportunities to narrow regional disparities in diagnosis and treatment and to reduce costs while improving efficiency. KingMed Diagnostics will leverage the network advantages of its nationwide intelligent medical diagnostic service platform to bring innovative pathology AI technology to primary-level healthcare.

Shares of Moderna and Novavax rose today after The New York Times reported that the US National Institutes of Health, or NIH, plans to launch a public-private partnership to accelerate the development of personalized cancer vaccines. The vaccine project is expected to begin in December, focusing on pancreatic cancer, liver cancer, and colorectal cancer, as well as certain tumors in children. Previous trials have used mRNA technology to train the body's immune system to recognize and attack proteins specific to cancer cells. The positive reaction to the news was most evident for Moderna, which is developing personalized mRNA cancer vaccines together with Merck. Moderna's share price has soared more than 600% since the start of this year, making it the best-performing stock among the companies used to calculate the S&P 500 index.

Vertex Pharmaceuticals announced new interim data showing that ALYFTREK, or vanzacaftor/tezacaftor/deutivacaftor, restored exocrine pancreatic function in some children with cystic fibrosis ages 2 to 5, allowing them to stop pancreatic enzyme replacement therapy. The data, presented as a late breaker poster at the North American Cystic Fibrosis Conference, came from 48 children enrolled in the PERT discontinuation substudy VX22-121-106 Cohort 2, part of an ongoing open-label extension study in that age group. After at least 48 weeks of treatment, mean fecal elastase-1 was 239.7 micrograms per gram, a mean increase of 110.2 micrograms per gram from baseline, and 48.6 percent of children reached the pancreatic sufficiency threshold of at least 200 micrograms per gram. Of the 48 children eligible for the substudy, 18, or 37.5 percent, successfully discontinued pancreatic enzyme replacement therapy for a mean duration of 8.6 weeks, and across the full enrolled cohort of 66 children, 50 percent were not on the therapy at the data cut. Carmen Bozic, Vertex's chief medical officer, said the findings represent a profound shift in understanding the benefits of treating cystic fibrosis in its earliest stages, noting that pancreatic failure had long been considered irreversible. Vertex also presented additional abstracts at the conference, held October 7 to 10 in Atlanta, on clinical and real-world evidence for CFTR modulators, including a post-hoc analysis of reduced intravenous antibiotic use with VNZ/TEZ/D-IVA in patients 12 and older and a natural history study of exocrine pancreatic function in infants under 12 months. The use of ALYFTREK in children 2 to 5 years old is investigational.

Johnson & Johnson said new long-term phase 3 data show its oral drug Icotyde, also known as icotrokinra, maintained high levels of skin clearance in plaque psoriasis patients after more than two years of treatment. In the placebo-controlled ICONIC-LEAD study, at least 72% of patients on the oral IL-23 receptor agonist achieved a Psoriasis Area and Severity Index score of 90, and at least 70% achieved clear or almost clear skin on the Investigator's Global Assessment 0/1 scale, from week 64 through week 112. Complete skin clearance also continued over that period, with at least 44% of Icotyde patients reaching PASI 100 and at least 46% achieving IGA 0, meaning clear skin. Improvements in itch were also seen from week 64 through week 112.

An exploratory analysis of Eli Lilly's ongoing phase 3b TOGETHER-PsO trial indicates that combining Taltz, or ixekizumab, with Zepbound, or tirzepatide, may improve both psoriasis and metabolic outcomes compared with Taltz alone. The trial enrolled patients with moderate-to-severe plaque psoriasis who were obese or overweight and who had at least one additional weight-related comorbid condition, randomizing them to receive Taltz plus Zepbound or Taltz alone. At week 36, participants who took the two treatments together saw better changes in psoriasis-specific, immune, and metabolic biomarkers than those in the Taltz monotherapy group, with changes noted in more psoriasis disease-associated and metabolic biomarkers. The trial's primary endpoint is the proportion of participants achieving both Psoriasis Area and Severity Index 100 and at least 10% weight reduction at week 36. Lilly noted that in the US, approximately 61% of individuals with psoriasis also have obesity or are overweight with at least one weight-related comorbidity.

GE HealthCare announced a definitive agreement on October 5 to acquire Sofie Biosciences for $945 million in cash, with closing expected in the first half of 2027. The deal builds on an exclusive licensing agreement struck in October 2023 covering development and commercialization of Fluorine-18 FAPI-74 outside the United States and global rights to Gallium-68 FAPI-46, and it would add U.S. rights to F-18 FAPI-74 while expanding GE HealthCare's domestic radiopharmaceutical manufacturing network. The company also recently received CE Mark approval for its Photonova Spectra photon-counting CT scanner, its third clearance across key geographies in five months. In the second quarter of fiscal 2026, adjusted EBIT margin fell 40 basis points year over year to 14.2%, though diluted EPS rose 16.5%, a figure that included a one-time $129 million tariff refund under the International Emergency Economic Powers Act. After $2.3 billion of strategic acquisitions in the first half, GE HealthCare reported $10.1 billion in total debt and $2.1 billion in cash and equivalents at quarter-end.

Pfizer has received U.S. FDA approval for TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy, expanding the drug into the frontline metastatic setting. The decision moves TUKYSA into an earlier phase of care for a broader patient group and reinforces Pfizer's growing emphasis on targeted oncology therapies, supported by Phase 3 HER2CLIMB-05 data. The approval fits Pfizer's narrative of shifting from a shrinking COVID portfolio toward a more oncology-led, specialty medicine story while keeping its sizeable dividend intact, though on its own it does not meaningfully change near-term dependence on cost savings and execution in obesity and oncology pipelines. Pfizer's narrative projects $54.3 billion in revenue and $9.1 billion in earnings by 2029, implying a 5.2% yearly revenue decline but an earnings increase of about $4.8 billion from $4.3 billion today, with a $28.88 fair value estimate representing 4% upside to the current price. The most relevant supporting development is Pfizer's fresh Phase 3 success with LITFULO in nonsegmental vitiligo, which, like TUKYSA, leans into higher value specialty care, while the recently affirmed US$0.43 quarterly dividend keeps income in focus.

AbbVie grew total revenue 10.2% to $16.99 billion last quarter even as Humira sales fell 35.9% to $756 million, with the company's newer immunology drugs carrying the growth. Skyrizi brought in $5.505 billion, up 24.4%, and Rinvoq added $2.525 billion, up 24.5%, lifting total immunology sales to $8.786 billion, up 15.1%. Neuroscience contributed $3.228 billion, up 20.3%, while oncology slipped 1.5% to $1.650 billion and aesthetics edged up 0.3% to $1.282 billion. Adjusted earnings per share came in at $3.65, up 22.9%, against GAAP earnings of $2.03, and management guides to full-year adjusted EPS of $13.87 to $14.07. AbbVie recently closed its purchase of Apogee Therapeutics at $135.11 per share in cash, for a total equity value of $10.9 billion, a deal the company says will reduce adjusted EPS by $0.14 this year and approximately $0.46 in 2027, with accretion beginning in 2032. At a forward P/E of 18.97 as of October 6, AbbVie trades essentially in line with the sector's 18.84 but above its own five-year average of 14.51, a premium that leans on expected EPS growth of 16.14% in 2027.

Eli Lilly reported 48% revenue growth for the second quarter of 2026 and raised its full-year outlook, yet the stock trades at 30.94 times forward earnings, well below its five-year average of 45.59. Mounjaro brought in $9.9 billion in the quarter, up 91%, and Zepbound added $4.9 billion, up 46%, while non-GAAP gross margin reached 86.3% and revenue outside the US rose 80% to $8.6 billion. The once-daily weight-loss pill Foundayo booked $98 million in its first quarter of sales, and Medicare's new coverage pathway now lets eligible patients get Foundayo or Zepbound for $50 a month, with Lilly estimating about 20 million Medicare patients may meet the clinical criteria. Management lifted 2026 revenue guidance to between $85 billion and $87 billion from $82 billion to $85 billion, and plans to file retatrutide with the FDA in the first quarter of 2027. Growth was volume-led, with volume up 60% against a 13% decline in realized prices, and second-quarter EPS of $8.38 absorbed $3.03 per share of acquired research charges, while reported EPS was $7.94 and full-year guidance stands at $35.50 to $36.50.

The FDA has approved Tecentriq and Tecentriq Hybreza, in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of stage III deficient DNA mismatch repair colon cancer, marking the 12th U.S. indication for Roche's cancer immunotherapy. The decision was based on the phase III ATOMIC study, which enrolled 712 patients with stage III dMMR colon cancer and showed that adding Tecentriq reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone, with a 36-month disease-free survival rate of 86% versus 76% for chemotherapy alone. The approval makes Tecentriq the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, and Roche plans additional regulatory filings including a submission to the European Medicines Agency. Tecentriq generated sales of CHF 1.7 billion in the first half of 2026, up 6%. Roche shares have risen 3.5% year to date.

Tandem Diabetes Care is broadening its product roadmap with new integrations, wider device compatibility and next-generation closed-loop technology while pushing international expansion. In second-quarter 2026, international sales rose 7% year over year to $75.3 million and pump shipments increased 19% to about 11,000, with direct-channel sales reaching about 13% of international revenues compared with 4% a year earlier. The company submitted a 510(k) for Mobi tubeless in the second quarter of 2026 and still targets a scaled launch in 2026 subject to FDA clearance, while Dexcom G7 15-day compatibility is now available for Mobi and t:slim X2 in the United States and t:slim X2 supports Abbott FreeStyle Libre 3 Plus in seven countries outside the United States. Tandem also received FDA approval of an IDE for its AIDANET fully closed-loop program and plans to begin a pivotal study later in 2026. Tandem ended the quarter with $456 million of cash, cash equivalents and short-term investments and no short-term debt, though a key infusion set supplier constrained supply sales and inventory, and the 10-Q states inventory constraints are expected to persist through 2026. The Zacks Consensus Estimate for Tandem's 2026 loss per share stands at 66 cents, indicating a year-over-year improvement of 74.4%, while 2026 revenues are pegged at $1.07 billion, a 5.7% increase from the year-ago reported number.

Eli Lilly is expected to post earnings of $9.83 per share for the current quarter, a year-over-year change of +40%, with the Zacks Consensus Estimate edging up +0.1% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $36.64 points to a change of +51.3% from the prior year and has risen +0.3% over the past month, while the next fiscal year's consensus estimate of $46.8 indicates a change of +27.7% and has moved +1.4% higher. On the revenue side, the consensus sales estimate of $22.14 billion for the current quarter points to a year-over-year change of +25.8%, with the $88.88 billion and $102.02 billion estimates for the current and next fiscal years indicating changes of +36.4% and +14.8%, respectively. In the last reported quarter, Lilly posted revenues of $22.97 billion, up +47.7% year over year, and EPS of $8.38 versus $6.31 a year ago, beating the Zacks Consensus revenue estimate of $20.26 billion by +13.38% and the EPS estimate by +39.43%. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Lilly, and the stock is graded D on the Zacks Value Style Score, indicating it trades at a premium to its peers.

Profound Medical Corp. and Telix Pharmaceuticals Limited have entered into a co-education agreement to advance PSMA-informed prostate care, the companies announced on October 9, 2026. The agreement establishes a framework to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's PSMA-targeting PET molecular imaging technologies, Gozellix and Illuccix, and Profound's MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO platform across the prostate care continuum. Planned initiatives include participation in major scientific and medical society meetings, key opinion leader programs, educational summits, speaker programs and webinars, along with educational content, clinical case studies and best-practice materials. Profound said the collaboration increases its access to urologists across the U.S. and internationally through a strong strategic partner, and that it is also developing PSMA-PET-MR image-fusion capabilities for a planned future release of its Treatment Delivery Console software. Profound CEO and Chairman Arun Menawat said the agreement supports broader market development and could strengthen the clinical and economic value proposition of TULSA-PRO centers, while Telix Precision Medicine CEO Kevin Richardson said the collaboration aims to increase awareness of the complementary roles of PSMA-PET imaging and MRI-guided therapy.

Novo Nordisk reported an FDA review update for its haemophilia A therapy denecimig, including manufacturing-related feedback, in October 2026. The FDA has kept the denecimig review open without giving a new action date, flagging manufacturing issues rather than problems with the FRONTIER efficacy or safety data, though Novo Nordisk says the extended review does not change its 2026 financial outlook. The pharmaceutical group also presented new CagriSema data on brain and metabolic pathway effects in obesity and diabetes at EASD 2026, alongside real-world evidence comparing clinical outcomes for semaglutide with tirzepatide in everyday practice. Novo Nordisk, a US based pharmaceuticals group with a market value of about DKK1.1 trillion, focuses on treatments for chronic conditions such as diabetes, obesity and blood disorders. The key signposts ahead are the EMA decision following the positive CHMP opinion for denecimig and the US FDA decision on the CagriSema obesity filing expected in the fourth quarter of 2026.

Teva Pharmaceutical Industries' fair value estimate was lifted from US$42.00 to US$45.30, an increase of about 7.9%, as analysts back the company's central nervous system transformation. The revised valuation came alongside a revenue growth adjustment from 2.25% to 1.94%, a net profit margin move from 13.09% to 15.01%, and a future P/E trimmed from 27.13x to 25.76x, while the discount rate held steady at 8.64%. TD Cowen initiated coverage with a US$55 price target, and Oppenheimer initiated with an Outperform rating and a US$50 price target, pointing to an acceleration phase and expected 2026 sales of US$3.7b from Austedo, Ajovy, and Uzedy. Both firms highlight Teva's approved neuropsychiatry and central nervous system agents as a key driver of growth potential, though Oppenheimer's multiyear launch cycle implies the company still needs consistent execution across a relatively narrow set of products. Teva is a global biopharma company combining a large base of generic and biosimilar products with a growing therapeutics pipeline that includes olanzapine LAI, ecopipam, DARI, emrusolmin, and duvakitug.

Danaher announced in early October 2026 that it had launched its first AI-powered autonomous lab at Abcam, combining artificial intelligence, robotics and connected workflows to accelerate the design, building and testing of custom antibodies and other molecular tools. The lab's closed-loop system feeds every experimental result back into its AI models, a setup intended to lift both the speed and scale of reagent discovery while maintaining rigorous validation. The launch reinforces Danaher's Life Sciences automation and AI catalyst but does not materially change near-term sensitivities around bioprocessing demand or the risk that softer respiratory testing and China pricing could leave overall growth below what the market currently embeds. The announcement comes alongside the appointment of Julie Sawyer Montgomery as CEO from 1 October 2026, with execution on connected, automated workflows expected to depend heavily on leadership continuity and capital allocation discipline. Danaher's narrative projects $31.7 billion revenue and $6.1 billion earnings by 2029, requiring 8.1% yearly revenue growth and about a $2.1 billion earnings increase from $4.0 billion today, while three Simply Wall St Community fair value estimates cluster in a tight US$225.66 to US$239.86 range.